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Tuberculosis (TB), caused by the respiratory pathogen Mycobacterium tuberculosis (Mtb) is
the leading cause of morbidity and mortality in patients coinfected with HIV-1. For the
majority of immunocompetent individuals, Mtb replication is contained, and progression to
active disease prevented by an orchestrated CD4+ T-cell specific and Th1-dominant immune
response [1]. These individuals are classified as latently infected with TB (LTBI) and have a
10% lifetime risk of developing TB [2]. The progressive and generalized CD4+ T-cell
depletion that occurs following HIV-1 infection increases the occurrence of TB disease in
LTBI individuals to a 10% annual risk [2]. Conversely, Mtb infection itself “aggravates” the
course of HIV-1 infection, increasing viral loads and acting as a predictor for worsening
clinical disease course [3].
Current estimates are that one third of the world’s population is infected with Mtb. Given
that annual HIV-1 infection rates are increasing (http://apps.who.int/globalatlas/dataQuary/
default.asp) [4], accurate diagnosis of both active and LTBI in HIV-1 positive individuals is
of significant clinical value. Yet, to date, there is no gold standard for diagnosis of LTBI.
Traditionally, the tuberculin skin test (TST) has been used to measure delayed
hypersensitivity reaction following intra-dermal injection of purified protein derivative
(PPD). However, the crude precipitate of Mtb culture supernatant (PPD) contains more than
200 proteins widely shared among mycobacteria, and consequently its use in the diagnosis
of LTBI lacks both specificity and sensitivity [5, 6]. More recently, IFN-γ release assays
(IGRA) such as QuantiFERON-TB Gold In-Tube and T-SPOT.TB have been developed [7].
IGRA improve the specificity of LTBI diagnosis by measuring cytokine production by
immune cells to Mtb-specific proteins, transcribed from genes not found in BCG and most
other environmental mycobacteria [7]. Early secreted antigenic target-6 and culture
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filtrate-10 are the two best studied to date and can improve the sensitivity of LTBI diagnosis
to 96% compared with 69% achieved by TST [7].
Despite the advantages of using IGRA over TST, questions have been raised as to the
usefulness of ex vivo IFN-γ-based T-cell assays in LTBI diagnosis in HIV-1 seropositive
individuals [8, 9]. HIV-1 infection is characterized by a reduction in the proliferative
capacity and IFN-γ response of Mtb-specific CD4+ T cells. This, when coupled with the
overall decline in CD4+ T-cell number and the poor concordance between different IGRA in
immunocompromised individuals [8, 9], has raised concern as to the sensitivity of these
assays in HIV-1 seropositive individuals [9–12], and prompted the Centre for
Communicable Diseases (USA) to recommend caution in the use of IGRA when testing
HIV-infected persons [13, 14].
To address these issues, we sought to further improve the sensitivity of conventional ex vivo
T.Spot, TB assays by specific expansion of TB-specific T cells in vitro. Cultured IFN-γ
ELISpot has been shown to increase the sensitivity of detection of low frequency and low
magnitude T-cell responses compared with standard ex vivo assays in a number of disease
settings [15–17]. The increased sensitivity is achieved by a 10-day, in vitro, peptide-
stimulated culture, during which PBMC are supplemented with lymphoproliferative and
anti-apoptotic cytokines (IL-2 and IL-7, respectively). Culture may enable expansion of
antigen-specific T-cell populations that are both different from and additional to those
detected by ex vivo assays to be measured [16].
Using a laboratory-modified version of the T-Sport. TB test, we initially screened 27 HIV-1
seronegative and 27 seropositive Malawian individuals for ex vivo Mtb-specific T-cell
responses. In accordance with current World Health Organisation (WHO) predictions and
previous literature reports [4, 18], we found 13/27 HIV-1-negative individuals had Mtb-
specific T-cell responses (48.1%) (Fig. 1A). On the contrary, HIV-1-positive participants
had a much lower frequency, with only 3/27 HIV-1 participants (11.1%), having detectable
Mtb-specific T-cell responses (Fig. 1B). We next compared the ex vivo responses detected
in a subset of these participants (26 HIV-1 negative and 22 HIV-1 positive) with those
observed following the cultured IFN-γ ELISpot technique. Briefly, 12/26 HIV-1
seronegative individuals had positive Mtb-specific T-cell responses detected ex vivo.
Following cultured ELISpot, the magnitude of Mtb-specific responses increased >20fold,
and, consistent with the previous studies [13–15, 17] the frequency at which Mtb-specific T-
cell responses were detected among HIV-1 seronegative individuals increased from 12/26 ex
vivo to 17/26 (65%) following cultured assay (Fig. 2A). More strikingly, a greater than 6-
fold increase in the detection of Mtb-specific T-cell responses was observed in HIV-1
seropositive individuals tested; 1/22 ex vivo to 7/22 following culture (Fig. 2B).
Importantly, Mtb-specific T-cell responses were detected in subjects with CD4 counts of
<200 cells/mm3, suggesting that this technique overcomes some of the difficulties observed
in applying IGRA to subjects with low CD4 counts [9, 12].
To examine whether the improved sensitivity resulted from nonspecific amplification or in
vitro priming, cultured Mtb-specific T-cell responses were compared between a population
in which Mtb infection is rare (UK – incidence 3%) and a population in which Mtb is
endemic (Malawi – 68%) [4, 18]. Following cultured ELISpot 26/41 (63%) HIV-1
seronegative, Malawian participants produced Mtb-specific T-cell responses (Supporting
Information Fig. 1A), whereas 1/14 (7%) UK participants tested positive (Supporting
Information Fig. 1B). Notably, the background for these assays was low and specific
expansion of Mtb T cells was not observed in the absence of peptide stimulation (data not
shown). The TB-specific response rates observed by cultured ELISpot are consistent with
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UK wide estimates of LTBI, suggesting that specificity was retained over the culture period
of the assay.
To our knowledge, this is the first demonstration that cultured IFN-γ ELISpot can be used to
improve the detection of Mtb-specific T-cell responses among HIV-1-positive individuals.
Notably, cultured PBMC can also be used for more detailed studies such as T-cell-epitope
mapping and phenotyping using flow cytometry (data not shown). Although we have shown
the cultured assay to be a reliable, experimental tool that is standardized for research
purposes, it is not validated clinically. Additional studies are now required to determine the
clinical relevance of cultured ELISpot responses and the LTBI rates in other cohorts from
both TB endemic and nonendemic regions. However, the low cell number requirements
mean that this technique should prove a valuable tool in future research of Mtb-specific T-
cell responses in both HIV-1-negative and - positive individuals.
In summary, these results confirm that current diagnostic techniques are underestimating
latent Mtb infection rates and provide methodology for more accurate and detailed analysis
of Mtb-specific responses in HIV-1/TB coinfection.
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Ex vivo IFN-γ ELISpot analysis of Mtb-specific responses in (A) 27 HIV-1 seronegative
individuals and (B) 27 HIV-1-positive individuals from Malawi. Data presented as the
number of spot forming units per million PBMC (SFU/106), following subtraction of mock-
stimulated wells (background). All assays were performed in quadruplicate using Mtb-
specific antigens (early secreted antigenic target-6 and culture filtrate-10), in addition to
positive control antigens (PPD, FEC and PHA). Positive response defined as greater than or
equal to 300 SFU/million PBMC, and or greater than 4× mock stimulation. Error bars
represent standard error of mean.
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Mtb-specific IFN-γ responses detected using ex vivo ELISpot analysis (solid bars) were
compared with responses detected following cultured IFN-γ ELISpot (hatched bars) in (A)
HIV-1-negative and (B) HIV-positive individuals. All data presented as average number of
SFU per million PBMC following background subtraction. Criteria for a positive response
were 4× mock-stimulated well and greater than 50 SFU/million PBMC (ex vivo assays) or
300 SFU/million PBMC (cultured assay). Error bars shown represent standard error of
mean.
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